Novartis comes to rescue of neurotic dogs

Article Abstract:

The Food and Drug Administration (FDA) gave its approval to Novartis AG's animal-health unit to sell a meat-flavored antidepressant drug for dogs. The drug is designed for dogs that experience "separation anxiety" and is also just one of many other pet behavorial treatments that are being developed by other drug firms. The drug is called Clomicalm when it is in a veterinary-use mode. It is the Anafranil drug, an old antidepressant treatment for humans.

Comment:

FDA approves of Novartis AG's meat-flavored antidepressant drug for dogs

Veterinary Drugs NEC, Product introduction, Novartis AG, Abstract, Veterinary drugs

---

U.S. approves Glaxo treatment for depression

Article Abstract:

GlaxoSmithKline PLC's Wellbutrin XL antidepressant has been approved in the U.S. Wellbutrin is a new version of GSK's antidepressants that are being threatened by generic rivals.

GlaxoSmithKline PLC, Wellbutrin (Medication)

---

AstraZeneca's Crestor should get U.S. approval

Article Abstract:

AstraZeneca PLC's Crestor anticholesterol drug has been approved in the U.S. The drug was approved by the US Food and Drug Administration.

Lipotropics & Cholesterol Reducers, AstraZeneca PLC, AZN, Anticholesteremic agents, Crestor (Medication)

Similar abstracts:

• Abstracts: Mom-tested ways to relieve camp jitters. The secret to smarter, healthier kids. No more morning grumpies
• Abstracts: Home truths: Th price of being a nation of property speculators. Death of owner occupation would herald dawn of an enlightened era
• Abstracts: New office created to rebuild Iraq. U.S. and Germany mend breach. U.S. considers scrapping Iraq sanctions unilaterally
• Abstracts: Airbus aims to trump Boeing's 7E7. Boeing seeks payment for failed job. Boeing trims satellite program
• Abstracts: Aventis refuses to yield to Sanofi: CEO dismisses hope for a friendly deal, plans asset split-off. Alnylam, Ribopharma to merge

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.